Gly-Gly-Gly-PEG4-DBCO

• CAT Number: I016046
• CAS Number: 2353409-80-8
• Molecular Formula: C₃₅H₄₆N₆O₉
• Molecular Weight: 694.77
• Purity: ≥95%
• Target: ADC Linker
• IUPAC Name: N-[2-[2-[2-[2-[2-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethyl]-4-(2-azatricyclo[10.4.0.04,9]hexadeca-1(16),4,6,8,12,14-hexaen-10-yn-2-yl)-4-oxobutanamide
• InChI: InChI=1S/C35H46N6O9/c36-23-32(43)39-25-34(45)40-24-33(44)38-14-16-48-18-20-50-22-21-49-19-17-47-15-13-37-31(42)11-12-35(46)41-26-29-7-2-1-5-27(29)9-10-28-6-3-4-8-30(28)41/h1-8H,11-26,36H2,(H,37,42)(H,38,44)(H,39,43)(H,40,45)
• InChIKey: IQIPCHLKYRUJEB-UHFFFAOYSA-N
• SMILES: C1C2=CC=CC=C2C#CC3=CC=CC=C3N1C(=O)CCC(=O)NCCOCCOCCOCCOCCNC(=O)CNC(=O)CNC(=O)CN

Gly-Gly-Gly-PEG4-DBCO（Cat No.:I016046） is a linker used in the development of antibody-drug conjugates (ADCs). This cleavable linker consists of four PEG units with a DBCO functional group, which can be conjugated with an appropriate drug molecule. The three glycine units in the linker can be enzymatically cleaved by proteases in the tumor microenvironment, thereby releasing the drug from the ADC.

Reference

[1]. Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017 May;16(5):315-337.